Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

30/07/2014 Barcelona among the top 10 cities in the world 24/07/2014 Researchers prove the effectiveness of a new drug against malaria using synchrotron light 17/07/2014 Creation of the Health Technologies Cluster 10/07/2014 An international team of scientists led by researchers from the UAB creates the world's first magnetic hose 03/07/2014 CaixaBank and Oracle set up a Big Data Centre of Excellence in the Barcelona Synchrotron Park 26/06/2014 The Barcelona Supercomputing Center hosts two important new international projects
39 40 41 42 43 44 45 46 47 48 49